

**Supplemental Table 1.**

**SCHEDULE OF STUDY EVENTS**

Procedures	Screening (Up to 1 wk)	Randomized (Wk 1, V1)	Treatment (Weeks 2-12) <sup>a</sup>	End of Treatment	Healing Confirmation
Informed consent	X				
Inclusion/exclusion	X	X			
Vital signs	X	X	X	X	
Screening labs	X				
Medical history	X				
Physical examination	X	As needed	As needed	As needed	
Wound history	X				
Vascular assessment	X				
Concomitant antibiotics	X	X	X	X	X
Demographics	X				
Wound assessment	X	X	X	X	X
Infection assessment	X	X	X	X	X
Off-loading assessment	X	X	X	X	
Participant education	X	X	X	X	X
Participant compliance			X	X	X
Randomization		X			
Aurix and UCC		X	X		
UCC only	X	X	X		
Assess adverse events		X	X	X	X
W-QOL		X		X	
Assess wound closure			X	X	
Confirm wound closure					X

Abbreviations: UCC, usual and customary care; W-QOL, Quality of Life with Chronic Wounds short-form instrument.

<sup>a</sup>If wound closure is not confirmed at week 12 for subjects treated with Aurix but with improved healing, treatment may continue for a maximum of 20 weeks from Wk 1 at the discretion of the patient and treating clinician.